1. Home
  2. OR vs RGEN Comparison

OR vs RGEN Comparison

Compare OR & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OR

Osisko Gold Royalties Ltd

HOLD

Current Price

$36.76

Market Cap

7.5B

ML Signal

HOLD

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$117.75

Market Cap

8.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OR
RGEN
Founded
2014
1981
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Medical/Dental Instruments
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5B
8.1B
IPO Year
2014
1995

Fundamental Metrics

Financial Performance
Metric
OR
RGEN
Price
$36.76
$117.75
Analyst Decision
Hold
Buy
Analyst Count
4
11
Target Price
$38.75
$173.09
AVG Volume (30 Days)
992.9K
840.9K
Earning Date
05-06-2026
04-28-2026
Dividend Yield
0.60%
N/A
EPS Growth
N/A
286.96
EPS
N/A
0.86
Revenue
N/A
$141,236,000.00
Revenue This Year
$100.08
$14.11
Revenue Next Year
$13.87
$14.71
P/E Ratio
$55.77
$136.91
Revenue Growth
N/A
35.10
52 Week Low
$18.99
$102.97
52 Week High
$48.06
$175.77

Technical Indicators

Market Signals
Indicator
OR
RGEN
Relative Strength Index (RSI) 30.65 35.89
Support Level $30.31 $113.07
Resistance Level $38.07 $132.51
Average True Range (ATR) 1.87 4.95
MACD -0.88 0.19
Stochastic Oscillator 0.70 24.57

Price Performance

Historical Comparison
OR
RGEN

About OR Osisko Gold Royalties Ltd

OR Royalties Inc, formerly Osisko Gold Royalties Ltd is engaged in the business of acquiring and managing precious metal and other high-quality royalties, streams and similar interests. The Company owns a portfolio of royalties, streams, offtakes, options on royalty/stream financings and exclusive rights to participate in future royalty/stream financings on various projects. Geographically, it generates majority of its income from North America and also generates some portions of income from South America, Australia, Africa and Europe.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: